Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
About this study
The aim of this trial is therefore to identify concomitant treatments with taking Tyrosine Kinase Inhibitor (=TKI) in the indication of Chronic Myeloid Leukemia (CML), whatever the stage of the disease, via pharmaceutical conciliation. These concomitant treatments as well as their dosages will be correlated with the TKI dosage since patients must have a sufficient residual concentration to be considered effective and to confirm adherence to treatment, the leading cause of treatment failure. In the event of unsatisfactory results, pharmaceutical interventions may take place: changes in treatments (TKI and not TKI) and / or dosages. In case of modification, a new dosage of TKI should be carried out.
- Condition
- Chronic Myeloid Leukemia
- Tested
- Pharmaceutical intervention
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Chronic Myeloid Leukemia
- Major patient;
- Patient affiliated to a social security scheme;
- Patient suffering from Chronic Myeloid Leukemia, taking a Tyrosine Kinase Inhibitor (Imatinib, Nilotinib, Dasatinib, or Bosutinib);
- Molecular response \< 4,5 Log;
Exclusion 3
- Legal incapacity or limited capacity ; Medical or psychological incapacity or limited capacity;
- Not able to read and/or to write French;
- Patient taking Ponatinib.
Where
1 site, 1 recruiting
CHU de Saint-Etienne
Saint-Etienne, France
Contact
-
Elisabeth DAGUENET, doctor of science
0477822875 elisabeth.daguenet@chu-st-etienne.fr
Potential match only. Final eligibility is determined by the study team.